Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFIXFc in previously untreated patients with severe hemophilia B
NL-OMON47235Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Safety of rFIXFc. Started May 2015; status: active, not recruiting.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON47235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47235.